S10 Safety and Long-Term Outcomes of Pediatric Therapeutics in Growth and Puberty Disorders

Program: Symposia
Clinical Session
Friday, April 1, 2016: 9:45 AM-11:15 AM
BR West (BCEC)
Chair:
Saul Malozowski, MD, PhD, MBA, National Institutes of Health, Bethesda, MD

Nothing to Disclose: SM
9:45 AM
Steven D. Chernausek, MD, Pediatrics, Section of Diabetes and Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Nothing to Disclose: SDC
10:15 AM
Erica A Eugster, MD, Dept of Pediatrics, Indiana Univ Schl of Med/Riley Hospital for Children, Indianapolis, IN
Disclosures:
EAE: Principal Investigator, Endo Pharmaceuticals.
10:45 AM
David Bruce Allen, MD, Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI
Nothing to Disclose: DBA
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire